3 Potential Catalysts That Could Lift Pfizer Stock Before 2025

Core Viewpoint - Pfizer's stock has seen a modest increase of 1.9% this year, and several upcoming catalysts could potentially drive its stock price higher before the end of 2024 [1] Group 1: Upcoming Catalysts - A phase 1 trial for a key obesity program is expected to report data soon, which could serve as a catalyst for the stock price despite previous mixed results from Pfizer's obesity candidate, danuglipron [2][4] - The phase 2 clinical trial for the obesity program is anticipated to start before the end of 2024, which may further influence investor sentiment [3] Group 2: Leadership Changes - Pfizer is nearing the conclusion of its search for a new Chief Scientific Officer (CSO), following the current CSO's departure after 15 years, which could significantly impact the company's strategic R&D decisions [5][6] - The appointment of a new CSO could lead to a positive market reaction, indicating potential future upside for the stock as the new leader begins to influence the company's direction [8] Group 3: Activist Investor Dynamics - The activist investor group Starboard Value has taken a $1 billion stake in Pfizer, aiming to push for improved business performance and possibly a new CEO, creating a situation that could either escalate into public conflict or lead to beneficial changes for shareholders [10][11] - Addressing the concerns raised by Starboard, particularly regarding budgeting and forecasting processes, could result in immediate positive impacts for shareholders, such as more reliable guidance updates [12]